{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:31:40Z","timestamp":1786379500272,"version":"build-2736575974"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment schedule complexity and route of administration may influence patient adherence and persistence. Limited real-world evidence exists comparing these outcomes across treatments for multiple sclerosis (MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine 18- and 24-month adherence\/persistence of ofatumumab (OMB) and other approved disease-modifying therapies (DMTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Optum Clinformatics\u00ae Data Mart data were used to identify adult patients with MS who initiated treatment with an approved DMT from August 20, 2019, to December 31, 2023. Patients were stratified into four treatment groups: OMB, infusion DMTs, oral DMTs, and other injectable DMTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After propensity score matching, adherence to OMB was significantly higher than to oral DMTs (18 months: 73% vs. 51% [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001]; 24 months: 69% vs. 47% [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001]) and was also higher with OMB than with other injectable agents (18 months: 74% vs. 40% [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001]; 24 months: 70% vs. 35% [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001]). Adherence to OMB and infusion DMTs was comparable (18 months: 74% vs. 70% [\n                      <jats:italic toggle=\"yes\">p\u2009=\u2009.<\/jats:italic>\n                      31]; 24 months: 70% vs. 65% [\n                      <jats:italic toggle=\"yes\">p\u2009=\u2009.<\/jats:italic>\n                      24]). Similar patterns were observed for persistence between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest OMB is a convenient, effective, self-administered alternative to infusion therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173261464369","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T17:49:29Z","timestamp":1786211369000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis"],"prefix":"10.1177","volume":"12","author":[{"given":"Ming-Hui","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Brown","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Taiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Vekeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Ionescu-Ittu","sequence":"additional","affiliation":[{"name":"STATLOG Inc, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0064-x"},{"key":"e_1_3_3_3_2","unstructured":"MS International Federation. Atlas of MS https:\/\/atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms (2025 accessed 4 November 2025)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.88.16_supplement.P2.052"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102539"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049"},{"key":"e_1_3_3_8_2","volume-title":"Tecfidera (package insert)","author":"Biogen Inc","year":"2024","unstructured":"Biogen Inc. Tecfidera (package insert). Biogen Inc, 2024."},{"key":"e_1_3_3_9_2","volume-title":"Aubagio (package insert)","author":"Genzyme Corp","year":"2024","unstructured":"Genzyme Corp. Aubagio (package insert). Genzyme Corp, 2024."},{"key":"e_1_3_3_10_2","volume-title":"Gilenya (package insert)","author":"Novartis Pharmaceuticals Corp","year":"2025","unstructured":"Novartis Pharmaceuticals Corp. Gilenya (package insert). Novartis Pharmaceuticals Corp, 2025."},{"key":"e_1_3_3_11_2","volume-title":"Ocrevus (package insert)","author":"Genentech Inc","year":"2026","unstructured":"Genentech Inc. Ocrevus (package insert). Genentech Inc, 2026."},{"key":"e_1_3_3_12_2","volume-title":"Tysabri (package insert)","author":"Biogen Inc","year":"2025","unstructured":"Biogen Inc. Tysabri (package insert). Biogen Inc, 2025."},{"key":"e_1_3_3_13_2","volume-title":"Kesimpta (package insert)","author":"Novartis Pharmaceuticals Corp","year":"2026","unstructured":"Novartis Pharmaceuticals Corp. Kesimpta (package insert). Novartis Pharmaceuticals Corp, 2026."},{"key":"e_1_3_3_14_2","volume-title":"Copaxone (package insert)","author":"Teva Neuroscience Inc","year":"2025","unstructured":"Teva Neuroscience Inc. Copaxone (package insert). Teva Neuroscience Inc, 2025."},{"key":"e_1_3_3_15_2","volume-title":"Rebif (package insert)","author":"EMD Serono","year":"2023","unstructured":"EMD Serono. Rebif (package insert). EMD Serono, 2023."},{"key":"e_1_3_3_16_2","volume-title":"Extavia (package insert)","author":"Novartis Pharmaceuticals Corp","year":"2023","unstructured":"Novartis Pharmaceuticals Corp. Extavia (package insert). Novartis Pharmaceuticals Corp, 2023."},{"key":"e_1_3_3_17_2","volume-title":"Betaseron (package insert)","author":"Bayer Healthcare Pharmaceuticals Inc","year":"2023","unstructured":"Bayer Healthcare Pharmaceuticals Inc. Betaseron (package insert). Bayer Healthcare Pharmaceuticals Inc, 2023."},{"key":"e_1_3_3_18_2","volume-title":"Avonex (package insert)","author":"Biogen Inc","year":"2023","unstructured":"Biogen Inc. Avonex (package insert). Biogen Inc, 2023."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512438239"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S130334"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2022.33288"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1857257"},{"key":"e_1_3_3_23_2","volume-title":"Existing claims-based algorithm may overestimate relapses in multiple sclerosis (MS) patients using infusible disease modifying therapies (DMTs) that require steroid premedication (P102)Congress of the European Committee for Treatment and Research in Multiple Sclerosis","author":"Hersh CM","year":"2022","unstructured":"Hersh CM, Conway DS, Chow W, et al. Existing claims-based algorithm may overestimate relapses in multiple sclerosis (MS) patients using infusible disease modifying therapies (DMTs) that require steroid premedication (P102). In: Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, Netherlands, 2022."},{"key":"e_1_3_3_24_2","first-page":"469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf DA","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002; 8: 469\u2013476.","journal-title":"J Manag Care Pharm"},{"key":"e_1_3_3_25_2","first-page":"639","article-title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. Commercial claims data","volume":"27","author":"Engmann NJ","year":"2021","unstructured":"Engmann NJ, Sheinson D, Bawa K, et al. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. Commercial claims data. J Manag Care Spec Pharm 2021; 27: 639\u2013649.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00319-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105888"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261464369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173261464369","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261464369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:16:28Z","timestamp":1786378588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173261464369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/20552173261464369"],"URL":"https:\/\/doi.org\/10.1177\/20552173261464369","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"20552173261464369"}}